Get the Stockscreener App
32.06
2.13%
0.67
After Hours:
32.06
Rigel Pharmaceuticals stock is traded at $32.06, with a volume of 382.23K.
It is up +2.13% in the last 24 hours and up +23.55% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
See More
Previous Close:
$31.39
Open:
$31.56
24h Volume:
382.23K
Relative Volume:
1.07
Market Cap:
$592.47M
Revenue:
$294.28M
Net Income/Loss:
$367.02M
P/E Ratio:
1.6953
EPS:
18.9115
Net Cash Flow:
$75.66M
1W Performance:
+7.84%
1M Performance:
+23.55%
6M Performance:
+14.05%
1Y Performance:
+88.15%
1-Day Range:
$31.56
$32.24
1-Week Range:
$28.78
$32.24
52-Week Range:
$16.05
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
32.06 | 580.09M | 294.28M | 367.02M | 75.66M | 18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
(RIGL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Why Rigel Pharmaceuticals Lost Big in December - AOL.com
Ritholtz Wealth Management Boosts Rigel Pharmaceuticals Holdings - National Today
Why VAALCO Energy, Rigel Pharmaceuticals, and Companhia Siderurgica Nacional Are Today's 3 Best Stoc - Yahoo
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel's 2026 Earnings Goal Sets Up Discounted Stock for Potential Clash With Analysts' 82% Price Projections - Bitget
Rigel Pharmaceuticals Was Easy To DismissNow It's Hard To Ignore (Rating Upgrade) - Seeking Alpha
Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance - MSN
Rigel Attracts Big Money as Charts Signal Caution - Bitget
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - StreetInsider
Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance Singapore
Aug Levels: What is the Moat Score of Rigel Pharmaceuticals IncWeekly Market Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Rigel Pharmaceuticals Grants Inducement RSUs to New Hires - National Today
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals Inc (FRA:RI2) Stock Price & 30 Year Financial Data - GuruFocus
RIGL PE Ratio & Valuation, Is RIGL Overvalued - Intellectia AI
Rigel Pharmaceuticals (RIGL) seeks approval for equity plan share increases at 2026 meeting - Stock Titan
How (RIGL) Movements Inform Risk Allocation Models - Stock Traders Daily
Rigel Pharmaceuticals Balances Breakout Growth With Caution - The Globe and Mail
Why Rigel Pharmaceuticals Shares Tanked - Yahoo
Hennion & Walsh Asset Management Inc. Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Jim Cramer blesses Rigel Pharmaceuticals as a spec as “it’s doing better than people realize” - MSN
Rigel Pharmaceuticals, Inc. (RIGL) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals’ pralsetinib shows efficacy in NSCLC clinical trial - TipRanks
Rigel Pharmaceuticals (RIGL) Reports Promising Results from ARRO - GuruFocus
Rigel announces publication of final ARROW clinical trial data on Gavreto® (pralsetinib) - marketscreener.com
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology - PR Newswire
Rigel Pharmaceuticals Receives 'Moderate Buy' Rating from Analysts - National Today
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Review: What is the Moat Score of Rigel Pharmaceuticals Inc2026 Highlights & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Jim Cramer Blesses Rigel Pharmaceuticals as a Spec as “It’s Doing Better Than People Realize” - Insider Monkey
Vanguard realignment leads to 0 shares reported for Rigel (RIGL) - Stock Titan
Jim Cramer Broke Down 16 Stocks Including Pharma Plays for Rising Oil - Insider Monkey
Rigel Pharmaceuticals (RIGL) Q4 earnings miss estimates - MSN
Rigel Pharmaceuticals Q4 2025 earnings preview - MSN
Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors - TipRanks
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure - Fierce Biotech
Rigel Pharmaceuticals shows rising relative strength; still shy of key benchmark - MSN
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? - MSN
Rigel enrols first subject in R289 Phase Ib expansion for MDS - MSN
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update - Quantisnow
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):